Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model.
about
Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and AldosteroneAn effective solution to discover synergistic drugs for anti-cerebral ischemia from traditional Chinese medicinal formulaeHydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: another inconvenient truthActivation of the central histaminergic system is involved in hypoxia-induced stroke tolerance in adult mice.Chronic aldosterone administration causes Nox2-mediated increases in reactive oxygen species production and endothelial dysfunction in the cerebral circulation.Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia.Neuroprotective Effect of Scutellarin on Ischemic Cerebral Injury by Down-Regulating the Expression of Angiotensin-Converting Enzyme and AT1 ReceptorMyeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex.Aldosterone and the mineralocorticoid receptor in the cerebral circulation and strokeInhibition of the renin-angiotensin system and target organ protection.Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β-HSDs to postangioplasty neointimal proliferation in mice.Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment.Cell-specific mineralocorticoid receptors: future therapeutic targets for stroke?The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia.Cell-specific mineralocorticoid receptors: future therapeutic targets for stroke?Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats.
P2860
Q26785911-D93C51F4-AAE6-42FD-9E13-4110D65C30E1Q28535072-11CD7570-F8AC-481F-90A9-5E6CE3E5CA1FQ30457642-B9551965-3A10-4A98-9200-83D883BCC278Q33620123-456A7AA0-A71A-4E49-BBD4-2ACACDBB37C2Q34117919-01263793-0097-4935-A1A1-341510B45594Q34591546-C550C1BD-F479-4351-A59D-3E4D28E9A7AAQ35885219-5EC03432-AC40-4B23-8A3A-CB21F0B2739FQ36522633-7C297ED9-1B35-4A5F-B591-545603223B56Q36548207-5A9C4ACD-B2EE-43E2-BCEE-B9F1D8EFF936Q37406883-351C878B-08AF-456E-81F8-678E2374868CQ37687150-9BE1BDC0-3590-465B-82C3-35B6FEC8D49CQ38108717-4E542EEB-35E8-4547-9CB1-0E3568AF7727Q38819193-84924BF7-871E-41DD-B447-96A464ECDFBEQ41064263-092A8BE2-F41B-43BE-AEEE-CDA3358486D0Q47146156-79D43D6F-FC01-4936-BA5D-C17041FD86E7Q54325969-8ECCFE8E-4D8D-46EB-BEB8-3FD1551CC052
P2860
Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@ast
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@en
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@nl
type
label
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@ast
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@en
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@nl
prefLabel
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@ast
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@en
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@nl
P2093
P1476
Pretreatment with eplerenone r ...... rebral artery occlusion model.
@en
P2093
Jian-Mei Li
Jun Iwanami
Kana Tsukuda
Li-Juan Min
Masaki Mogi
Masaru Iwai
Masatsugu Horiuchi
Shoko Okamoto
Xin-Yu Gao
P304
P356
10.1016/J.EJPHAR.2007.03.043
P407
P577
2007-03-31T00:00:00Z